Ignite Creation Date:
2024-05-05 @ 5:04 PM
Last Modification Date:
2024-10-26 @ 9:27 AM
Study NCT ID:
NCT00372723
Status:
WITHDRAWN
Last Update Posted:
2013-04-26
First Post:
2006-09-05
Brief Title:
Study of a Potential New Treatment for Patients With Toxic Epidermal Necrolysis TEN
Sponsor:
Loyola University
Organization:
Loyola University
Study Overview
Official Title:
Pilot Study Comparing Remicade Infliximab vs Standard Care in the Treatment of Toxic Epidermal Necrolysis
Status:
WITHDRAWN
Status Verified Date:
2013-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
slow enrollment
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To determine whether treatment of patients who have toxic epidermal necrolysis with a drug called remicaide increases the number of patients who are alive 30 days laters
Detailed Description:
This is a pilot preliminary study Patients with a diagnosis of TEN will be asked to consider participating The study intervention is a single intravenous dose of remicaide 5 mgkg Standard supportive care will be given The percentage of patients alive at 30 days after treatment with remicaide will be compared to historical controls
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None